Evidence map›Paper›PMID 35311573›Full record

ReviewMicrobiology spectrum2022

Luciferase Immunosorbent Assay Based on Multiple E Antigens for the Detection of Chikungunya Virus-Specific IgG Antibodies.

Xiaoxia Li, Xuan Wan, Jinyue Liu, Haiying Wang, Anan Li, Changwen Ke, Shixing Tang, Wei Zhao, Shaoxi Cai, Chengsong Wan

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Revisiting the emergence of the Chikungunya virus in Alagoas, Northeast of Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Xiaoxia Li *BSL-3 Laboratory, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Xuan Wan *Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Jinyue LiuBSL-3 Laboratory, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Haiying WangDepartment of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China.
Anan LiGuangdong Center for Disease Control and Prevention, Guangzhou, China.
Changwen KeGuangdong Center for Disease Control and Prevention, Guangzhou, China.
Shixing TangDepartment of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, China.ORCID 0000-0001-9637-1874
Wei ZhaoBSL-3 Laboratory, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Shaoxi CaiDepartment of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Chengsong WanBSL-3 Laboratory, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.ORCID 0000-0001-6847-8658
Southern Medical University · CNGuangzhou Center for Disease Control and Prevention · CNNanfang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the chikungunya virus (CHIKV) has continued to spread from local epidemics to nonnative habitats until eventually reaching pandemic status. Nonendemic areas such as China have also emerged as potential epidemic areas of CHIKV. Serological detection of CHIKV is the key to diagnosing and controlling the prevalence of this virus. In this study, we review the progress of the serological detection of the envelope (E) protein in CHIKV, and we provide a novel research assay and ideas for the serological detection of CHIKV. The luciferase immunosorbent assay (LISA) does not require species-specific labeled secondary antibodies for detection, making it universally suitable for tracking samples from various animals or carriers. At present, most research on CHIKV antigen detection technology tends to combine two or more proteins to avoid the decrease in detection ability caused by antigen mutation. Our results indicate that two or more kinds of CHIKV E antigens combined with LISA detection can improve the detection rate of anti-CHIKV immunoglobulin G (IgG) antibodies in CHIKV-infected patient sera and detect antibodies in the early stage of infection accurately and sensitively. After 235 days of infection, the anti-CHIKV IgG antibodies could still be detected in CHIKV-infected patients. All serum samples were tested with a detection rate of 100% after combining various recombinant CHIKV E antigens. Our proposed CHIKV-specific LISA could be a useful tool for serum diagnosis of CHIKV infection and serum epidemic research in areas where CHIKV is endemic, which would help to manage potential epidemics in the future.

Indexed as

Chikungunya FeverChikungunya virusAnimalsAntibodies, ViralHepatitis B e AntigensHumansImmunoglobulin GImmunosorbentsLuciferasesAntibodies, ViralHepatitis B e AntigensImmunoglobulin GImmunosorbentsLuciferaseschikungunya virus (CHIKV)CHIKV antibodiesenvelope (E) antigensenvelope proteinluciferase immunosorbent assay (LISA)

Identifiers

PMID35311573
PMCPMC9045172
OpenAlexW4220903673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.